References
Lambin P, Leijenaar RTH, Deist TM et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14(12):749–762
Smith CP, Czarniecki M, Mehralivand S et al (2019) Radiomics and radiogenomics of prostate cancer. Abdom Radiol (NY) 44(6):2021–2029
Sushentsev N, Rundo L, Abrego L et al (2023) Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance. Eur Radiol. https://doi.org/10.1007/s00330-023-09438-x
Sushentsev N, Rundo L, Blyuss O et al (2021) MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance. Sci Rep 11(1):12917
Sushentsev N, Rundo L, Blyuss O et al (2022) Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance. Eur Radiol 32(1):680–689
Walker CH, Marchetti KA, Singhal U, Morgan TM (2022) Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes. World J Urol 40(1):35–42
Moore CM, Giganti F, Albertsen P et al (2017) Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations-a report of a European School of Oncology Task Force. Eur Urol 71(4):648–655
Rajwa P, Pradere B, Quhal F et al (2021) Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis. Eur Urol 80(5):549–563
Caglic I, Sushentsev N, Gnanapragasam VJ et al (2021) MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance. Eur Radiol 31(5):2696–2705
Funding
The authors state that this work has not received any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Sonia Gaur.
Conflict of interest
Sonia Gaur, MD, reports royalties from the National Institutes of Health for licensed intellectual property in artificial intelligence technology in prostate MRI.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Informed consent
NA
Ethical approval
NA
Study subjects or cohorts overlap
NA
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This comment refers to the article available at https://doi.org/10.1007/s00330-023-09438-x
Rights and permissions
About this article
Cite this article
Gaur, S. Commentary: considering radiomics in the setting of prostate cancer active surveillance. Eur Radiol 33, 3789–3791 (2023). https://doi.org/10.1007/s00330-023-09634-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-023-09634-9